SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
Policy
Biopharma Update on the Novel Coronavirus: May 22
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
May 22, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
May 21, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Policy
U.S. Government Provides AstraZeneca More Than $1 Billion for COVID-19 Vaccine
The U.S. Biomedical Advanced Research and Development Authority (BARDA) paid more than $1 billion to support the development, production and delivery of the vaccine beginning this fall.
May 21, 2020
 · 
7 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 20
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
May 20, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
FDA
Lynparza Becomes Second PARP Inhibitor Approved for Prostate Cancer, Just Days Behind the First
Clovis Oncology’s Rubraca remained the only PARP inhibitor approved for prostate cancer for only a handful of days. Today, that medication is joined by AstraZeneca’s and Merck’s powerhouse PARP inhibitor, Lynparza.
May 20, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
AstraZeneca Aims for 30 Million Doses of COVID-19 Vaccine for U.K. by September
AstraZeneca reported it plans to manufacture as much as 30 million doses of the vaccine for the U.K. market by September, with expectations of 100 million doses by the end of the year.
May 18, 2020
 · 
5 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 18
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
May 18, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
TARPEYO is the first FDA-approved drug for immunog
FDA
AstraZeneca and Merck’s Lynparza Approved For Ovarian Cancer Just a Week After GSK’s Zejula
The Lynparza approval isn’t as broad as the Zejula approval, with Lynparza not approved for use in patients with homologous recombination deficiencies.
May 11, 2020
 · 
3 min read
 · 
Mark Terry
Courtesy of Alexanderstock23/Shutterstock
FDA
FDA Approves AstraZeneca’s Farxiga for Heart Failure in Adults with Reduced Ejection Fraction
The drug can potentially reduce the risk of cardiovascular death and hospitalization for heart failure.
May 6, 2020
 · 
3 min read
 · 
Krystle Vermes
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Press Releases
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 24, 2026
 · 
19 min read
Press Releases
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
May 22, 2026
 · 
19 min read
Load More